World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
154
Citations
112970
World Ranking
989
National Ranking
565

John C. Byrd publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John C. Byrd sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,461 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John C. Byrd D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John C. Byrd sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 154 D-Index — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2007 - Fellow of the American Association for the Advancement of Science (AAAS)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

John C. Byrd is affiliated with the University of Cincinnati in the United States and has contributed extensively to the fields of Medicine, Biochemistry, Genetics, and Molecular Biology. Their research covers subfields including Pathology and Forensic Medicine, Genetics, Molecular Biology, Oncology, and Hematology.

The scientist's main research topics include:

  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Sphingolipid Metabolism and Signaling
  • Pharmacological Effects of Natural Compounds
  • Drug Transport and Resistance Mechanisms
  • Lung Cancer Treatments and Mutations

John C. Byrd has published research in various venues, contributing multiple papers to the following publication sources:

  • UNC Libraries
  • Hematological Oncology
  • The AAPS Journal
  • Blood
  • Clinical Epigenetics

Notable recent papers by this researcher include:

  • Genetic heterogeneity of diffuse large B-cell lymphoma (2020), published in UNC Libraries
  • Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia (2024), published in Hematological Oncology
  • Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats (2020), published in The AAPS Journal
  • Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies (2024), published in Blood
  • Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002 (2020), published in UNC Libraries

The researcher collaborates frequently with several colleagues, including:

  • David A. Rizzieri
  • Kathleen A. Burke
  • Brian Dougherty
  • Veerendra Munugalavadla
  • Richard R. Furman

Among professional recognitions, John C. Byrd was named a Fellow of the American Association for the Advancement of Science (AAAS) in 2007 and holds membership in the Association of American Physicians.

Best Publications

  • Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

    Ash A. Alizadeh;Michael B. Eisen;R. Eric Davis;Izidore S. Lossos

  • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellstrom-Lindberg;Valeria Santini

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

    John C. Byrd;Krzysztof Mrózek;Richard K. Dodge;Andrew J. Carroll

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

    Andreas Rosenwald;Ash A. Alizadeh;George Widhopf;Richard Simon

  • Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

    Jennifer A. Woyach;Richard R. Furman;Ta Ming Liu;Hatice Gulcin Ozer

  • Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

    Michael J. Keating;Ian Flinn;Vinay Jain;Jacques-Louis Binet

  • ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

    Laura Z. Rassenti;Lang Huynh;Tracy L. Toy;Liguang Chen

  • MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

    Ramiro Garzon;Shujun Liu;Muller Fabbri;Zhongfa Liu

  • Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Bonnie Harrington;Susan O'Brien;Jeffrey A. Jones

  • Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

    Sarah E. M. Herman;Amber L. Gordon;Erin Hertlein;Asha Ramanunni

  • The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

    Don M. Benson;Courtney E. Bakan;Anjali Mishra;Craig C. Hofmeister

  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    Jennifer A Woyach;Amy S Ruppert;Nyla A Heerema;Weiqiang Zhao

  • Frequency of Prolonged Remission Duration after High-Dose Cytarabine Intensification in Acute Myeloid Leukemia Varies by Cytogenetic Subtype

    Clara D. Bloomfield;David Lawrence;John C. Byrd;Andrew Carroll

  • Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

    Jason A. Dubovsky;Kyle A. Beckwith;Gayathri Natarajan;Jennifer A. Woyach

  • CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

    Brian J. Lannutti;Sarah A. Meadows;Sarah E. M. Herman;Adam Kashishian

  • Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

    John C. Byrd;Bercedis L. Peterson;Vicki A. Morrison;Kathleen Park

  • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Jan A. Burger

Frequent Co-Authors

Michael R. Grever
Michael R. Grever The Ohio State University
Nyla A. Heerema
Nyla A. Heerema The Ohio State University
Guido Marcucci
Guido Marcucci City Of Hope National Medical Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Jennifer R. Brown
Jennifer R. Brown Harvard University
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
Steven Coutre
Steven Coutre Stanford University
Clara D. Bloomfield
Clara D. Bloomfield The Ohio State University
Peter Hillmen
Peter Hillmen St James's University Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t have to follow a single, traditional route. Many students choose online degrees to enter healthcare more quickly or from a non-traditional background. For example, fast track lpn programs are designed for those seeking a quicker entry into nursing, allowing students to become Licensed Practical Nurses faster than through standard pathways.

For those interested in advanced patient care, particularly in mental health, online pmhnp programs provide flexible options to become a Psychiatric Mental Health Nurse Practitioner. These programs can open doors to specialized roles and address the growing need for mental health professionals.

Not all healthcare roles involve direct patient care. Students interested in the business and leadership side of medicine may opt for an online health management degree, ideal for those aiming to manage hospitals, clinics, or other medical facilities. For a more advanced credential at a lower cost, the cheapest online mha programs offer a path to a master’s degree in health administration.

These diverse online pathways make healthcare education more accessible and adaptable to suit different goals and schedules, supporting a wide range of rewarding careers beyond traditional medical school.

Best Scientists Citing John C. Byrd

Trending Scientists

Recently Published Articles